459 related articles for article (PubMed ID: 18058202)
1. On the rate and extent of drug delivery to the brain.
Hammarlund-Udenaes M; Fridén M; Syvänen S; Gupta A
Pharm Res; 2008 Aug; 25(8):1737-50. PubMed ID: 18058202
[TBL] [Abstract][Full Text] [Related]
2. Innovative in vitro method to predict rate and extent of drug delivery to the brain across the blood-brain barrier.
Mangas-Sanjuan V; González-Álvarez I; González-Álvarez M; Casabó VG; Bermejo M
Mol Pharm; 2013 Oct; 10(10):3822-31. PubMed ID: 23977999
[TBL] [Abstract][Full Text] [Related]
3. Quantitative investigation of the brain-to-cerebrospinal fluid unbound drug concentration ratio under steady-state conditions in rats using a pharmacokinetic model and scaling factors for active efflux transporters.
Kodaira H; Kusuhara H; Fuse E; Ushiki J; Sugiyama Y
Drug Metab Dispos; 2014 Jun; 42(6):983-9. PubMed ID: 24644297
[TBL] [Abstract][Full Text] [Related]
4. Revisiting atenolol as a low passive permeability marker.
Chen X; Slättengren T; de Lange ECM; Smith DE; Hammarlund-Udenaes M
Fluids Barriers CNS; 2017 Oct; 14(1):30. PubMed ID: 29089037
[TBL] [Abstract][Full Text] [Related]
5. Unbound Brain-to-Plasma Partition Coefficient, K
Loryan I; Reichel A; Feng B; Bundgaard C; Shaffer C; Kalvass C; Bednarczyk D; Morrison D; Lesuisse D; Hoppe E; Terstappen GC; Fischer H; Di L; Colclough N; Summerfield S; Buckley ST; Maurer TS; Fridén M
Pharm Res; 2022 Jul; 39(7):1321-1341. PubMed ID: 35411506
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of pericyte involvement in small-molecular drug transport across the blood-brain barrier.
Mihajlica N; Betsholtz C; Hammarlund-Udenaes M
Eur J Pharm Sci; 2018 Sep; 122():77-84. PubMed ID: 29933077
[TBL] [Abstract][Full Text] [Related]
7. Integrating in Silico and in Vitro Approaches To Predict Drug Accessibility to the Central Nervous System.
Zhang YY; Liu H; Summerfield SG; Luscombe CN; Sahi J
Mol Pharm; 2016 May; 13(5):1540-50. PubMed ID: 27015243
[TBL] [Abstract][Full Text] [Related]
8. Blood-brain barrier transport helps to explain discrepancies in in vivo potency between oxycodone and morphine.
Boström E; Hammarlund-Udenaes M; Simonsson US
Anesthesiology; 2008 Mar; 108(3):495-505. PubMed ID: 18292687
[TBL] [Abstract][Full Text] [Related]
9. Rate and extent of mitragynine and 7-hydroxymitragynine blood-brain barrier transport and their intra-brain distribution: the missing link in pharmacodynamic studies.
Yusof SR; Mohd Uzid M; Teh EH; Hanapi NA; Mohideen M; Mohamad Arshad AS; Mordi MN; Loryan I; Hammarlund-Udenaes M
Addict Biol; 2019 Sep; 24(5):935-945. PubMed ID: 30088322
[TBL] [Abstract][Full Text] [Related]
10. Molecular properties determining unbound intracellular and extracellular brain exposure of CNS drug candidates.
Loryan I; Sinha V; Mackie C; Van Peer A; Drinkenburg WH; Vermeulen A; Heald D; Hammarlund-Udenaes M; Wassvik CM
Mol Pharm; 2015 Feb; 12(2):520-32. PubMed ID: 25496026
[TBL] [Abstract][Full Text] [Related]
11. Prediction of brain:blood unbound concentration ratios in CNS drug discovery employing in silico and in vitro model systems.
Liu H; Dong K; Zhang W; Summerfield SG; Terstappen GC
Drug Discov Today; 2018 Jul; 23(7):1357-1372. PubMed ID: 29548981
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Methods for Estimating Unbound Intracellular-to-Medium Concentration Ratios in Rat and Human Hepatocytes Using Statins.
Yoshikado T; Toshimoto K; Nakada T; Ikejiri K; Kusuhara H; Maeda K; Sugiyama Y
Drug Metab Dispos; 2017 Jul; 45(7):779-789. PubMed ID: 28468836
[TBL] [Abstract][Full Text] [Related]
13. Methodologies to assess brain drug delivery in lead optimization.
Hammarlund-Udenaes M; Bredberg U; Fridén M
Curr Top Med Chem; 2009; 9(2):148-62. PubMed ID: 19200002
[TBL] [Abstract][Full Text] [Related]
14. Application of unbound liver-to-plasma concentration ratio to quantitative projection of cytochrome P450-mediated drug-drug interactions using physiologically based pharmacokinetic modelling approach.
Iwasaki S; Kosugi Y; Zhu AZX; Nakagawa S; Sano N; Funami M; Kosaka M; Furuta A; Hirabayashi H; Amano N
Xenobiotica; 2019 Nov; 49(11):1251-1259. PubMed ID: 30516093
[TBL] [Abstract][Full Text] [Related]
15. Successful Prediction of Human Steady-State Unbound Brain-to-Plasma Concentration Ratio of P-gp Substrates Using the Proteomics-Informed Relative Expression Factor Approach.
Storelli F; Anoshchenko O; Unadkat JD
Clin Pharmacol Ther; 2021 Aug; 110(2):432-442. PubMed ID: 33675056
[TBL] [Abstract][Full Text] [Related]
16. The brain slice method for studying drug distribution in the CNS.
Loryan I; Fridén M; Hammarlund-Udenaes M
Fluids Barriers CNS; 2013 Jan; 10(1):6. PubMed ID: 23336814
[TBL] [Abstract][Full Text] [Related]
17. How Much is Enough? Impact of Efflux Transporters on Drug delivery Leading to Efficacy in the Treatment of Brain Tumors.
Zhang W; Oh JH; Zhang W; Rathi S; Le J; Talele S; Sarkaria JN; Elmquist WF
Pharm Res; 2023 Nov; 40(11):2731-2746. PubMed ID: 37589827
[TBL] [Abstract][Full Text] [Related]
18. Brain Distribution of Drugs: Pharmacokinetic Considerations.
Loryan I; Hammarlund-Udenaes M; Syvänen S
Handb Exp Pharmacol; 2022; 273():121-150. PubMed ID: 33258066
[TBL] [Abstract][Full Text] [Related]
19. Muscle to Brain Partitioning as Measure of Transporter-Mediated Efflux at the Rat Blood-Brain Barrier and Its Implementation into Compound Optimization in Drug Discovery.
Cui Y; Lotz R; Rapp H; Klinder K; Himstedt A; Sauer A
Pharmaceutics; 2019 Nov; 11(11):. PubMed ID: 31718023
[TBL] [Abstract][Full Text] [Related]
20. Investigation of utility of cerebrospinal fluid drug concentration as a surrogate for interstitial fluid concentration using microdialysis coupled with cisternal cerebrospinal fluid sampling in wild-type and Mdr1a(-/-) rats.
Nagaya Y; Nozaki Y; Takenaka O; Watari R; Kusano K; Yoshimura T; Kusuhara H
Drug Metab Pharmacokinet; 2016 Feb; 31(1):57-66. PubMed ID: 26830080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
